Focused On-demand Library for Exonuclease 3'-5' domain-containing protein 2

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q9NVH0

UPID:
EXD2_HUMAN

ALTERNATIVE NAMES:
3'-5' exoribonuclease EXD2; Exonuclease 3'-5' domain-like-containing protein 2

ALTERNATIVE UPACC:
Q9NVH0; B4DIH6; G5E947; Q6AWB6; Q8N3D3

BACKGROUND:
The protein Exonuclease 3'-5' domain-containing protein 2, with alternative names such as 3'-5' exoribonuclease EXD2, plays a versatile role in cellular mechanisms. It is essential for both RNA and DNA processing, mitochondrial health, and the cellular response to DNA damage, showcasing its exoribonuclease and exodeoxyribonuclease activities under different conditions.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Exonuclease 3'-5' domain-containing protein 2 holds promise for unveiling novel therapeutic avenues.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8058 of 8789